ADICON Clinical LaboratoryADICON Clinical Laboratory

Industry Updates

  • Genetic key to severe malaria resistance uncovered

    Researchers have identified two genetic variants linked with human resistance to severe malaria.
    The team believes that the single nucleotide polymorphisms (SNPs), located within the ATP2B4 gene on chromosome 1 (rs4951074) and near MARVELD3 on chromosome 16 (rs2334880), may confer resistan...

  • Researchers reveal possible drug targets to combat anthrax

    A trawl of the genome of the deadly bacterium Bacillus anthracis has revealed a clutch of targets for new drugs to combat an epidemic of anthrax or a biological weapons attack. The targets are all proteins that are found in the bacteria but not in humans and are involved in diverse bacterial proc...

  • Three alternative diabetes markers found

    Experts have identified three alternative biomarkers that may be useful for picking up on diabetes risk.
    In a study of individuals who were initially free of the condition, baseline levels of fructosamine, glycated albumin, and 1,5 anhydroglucitol (1,5-AG) strongly predicted diabetes.

  • Cepheid launches new Xpert BCR-ABL Monitor test

    Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert® BCR-ABL Monitor test, now incorporating lot-specific standardization using the WHO (World Health Organization) BCR-ABL standards. The test is being released as a European CE-IVD Mark product under the European Directive o...

  • Vorinostat drives HIV from hiding

    The addition of vorinostat to current antiretroviral therapy (ART) regimens can potentially help to eradicate hidden pockets of dormant human immunodeficiency virus (HIV), according to study results published in Nature.

    Persistent reservoirs of dormant HIV often remain despite years of tr...

  • Lung cancer patients can be screened for ALK-inhibitor suitability

    Anaplastic lymphoma kinase (ALK) gene status in patients with lung adenocarcinoma can be determined non-invasively using circulating tumor cells (CTCs), research shows.
    Since patients with altered ALK show "an outstanding favourable response" to targeted inhibition, the findings ...

  • Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

    Published on August 16, 2011 at 4:51 AM?·?No Comments

    QIAGEN (NASDAQ: QGEN;?Frankfurt, Prime Standard: QIA) today announced it has entered into a partnership with Pfizer Inc. (NYSE: PFE) for the development of a companion molecular diagnostic test for use with an investigation...

  • FDA clears IQuum's Liat influenza A/B assay, analyzer

     Published on August 23, 2011 at 8:07 AM?·?No Comments

    IQuum, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Liat??Influenza?A/B Assay and the Liat? Analyzer. This molecular diagnostic test is an automated sam...
Page 2 of 2 << Previous 1 2 Next >>